Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan.
School of Life Sciences and Biotechnology, and Joint Laboratory of International Cooperation in Metabolic and Developmental Sciences, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China.
Intervirology. 2021;64(2):55-68. doi: 10.1159/000513686. Epub 2021 Jan 15.
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) epidemic has resulted in thousands of infections and deaths worldwide. Several therapies are currently undergoing clinical trials for the treatment of SARS-CoV-2 infection. However, the development of new drugs and the repositioning of existing drugs can only be achieved after the identification of potential therapeutic targets within structures, as this strategy provides the most precise solution for developing treatments for sudden epidemic infectious diseases.
In the current investigation, crystal and cryo-electron microscopy structures encoded by the SARS-CoV-2 genome were systematically examined for the identification of potential drug targets. These structures include nonstructural proteins (Nsp-9; Nsp-12; and Nsp-15), nucleocapsid (N) proteins, and the main protease (Mpro). Key Message: The structural information reveals the presence of many potential alternative therapeutic targets, primarily involved in interaction between N protein and Nsp3, forming replication-transcription complexes (RTCs) which might be a potential drug target for effective control of current SARS-CoV-2 pandemic. RTCs consist of 16 nonstructural proteins (Nsp1-16) that play the most essential role in the synthesis of viral RNA. Targeting the physical linkage between the envelope and single-stranded positive RNA, a process facilitated by matrix proteins may provide a good alternative strategy. Our current study provides useful information for the development of new lead compounds against SARS-CoV-2 infections.
严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)疫情已在全球范围内导致数千例感染和死亡。目前有几种疗法正在进行临床试验,以治疗 SARS-CoV-2 感染。然而,只有在确定结构内的潜在治疗靶点后,才能开发新药和重新定位现有药物,因为这种策略为突发传染病的治疗提供了最精确的解决方案。
在目前的研究中,系统地检查了 SARS-CoV-2 基因组编码的晶体和冷冻电子显微镜结构,以确定潜在的药物靶点。这些结构包括非结构蛋白(Nsp-9;Nsp-12;和 Nsp-15)、核衣壳(N)蛋白和主要蛋白酶(Mpro)。
结构信息揭示了许多潜在的替代治疗靶点的存在,这些靶点主要涉及 N 蛋白与 Nsp3 之间的相互作用,形成复制转录复合物(RTCs),这可能是有效控制当前 SARS-CoV-2 大流行的潜在药物靶点。RTCs 由 16 种非结构蛋白(Nsp1-16)组成,在病毒 RNA 的合成中发挥着最重要的作用。靶向包膜与单链正 RNA 之间的物理连接,这一过程由基质蛋白介导,可能提供一种很好的替代策略。我们目前的研究为开发针对 SARS-CoV-2 感染的新先导化合物提供了有用的信息。